Poolbeg Pharma
POLB · AIM · Health Care · mcap £46m · 6.4p
Poolbeg develops medicines for cancer immunotherapy-induced cytokine release syndrome (POLB 001) and an oral GLP-1 delivery technology for obesity. It aims to partner or commercialise these assets and holds patents and FDA Orphan Drug Designation for POLB 001.
| Target | Promise | Said | Status |
|---|---|---|---|
| Today · 2 Nov 2026 | |||
| 2028 | |||
| Q2 2028 | Fund TOPICAL and oral GLP-1 proof-of-concept trials through to completion | 14 Jul 2026 | … In progress |
|
Status so far
Not yet due. |
|||